(Q51785555)

12 April 2018

title

Survival outcome and predictors of gefitinib antitumor activity in East Asian chemonaive patients with advanced nonsmall cell lung cancer. (English)

1 reference

12 April 2018

author

Chong-Jen Yu

4

1 reference

12 April 2018

author name string

Chih-Hsin Yang

1

1 reference

12 April 2018

Jin-Yuan Shih

2

1 reference

12 April 2018

Kun-Chieh Chen

3

1 reference

12 April 2018

Tsung-Ying Yang

5

1 reference

12 April 2018

Ching-Pei Lin

6

1 reference

12 April 2018

Wen-Pin Su

7

1 reference

12 April 2018

Chien-Hung Gow

8

1 reference

12 April 2018

Chiun Hsu

9

1 reference

12 April 2018

Gee-Chen Chang

10

1 reference

12 April 2018

Pan-Chyr Yang

11

1 reference

12 April 2018

language of work or name

English

0 references

publication date

1 October 2006

1 reference

12 April 2018

published in

Cancer

1 reference

12 April 2018

volume

107

1 reference

12 April 2018

issue

8

1 reference

12 April 2018

page(s)

1873-1882

1 reference

12 April 2018

Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22220

7 January 2021

Dose-comparative monotherapy trials of ZD1839 in previously treated non-small cell lung cancer patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22220

7 January 2021

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22220

7 January 2021

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22220

7 January 2021

Gefitinib (ZD1839) monotherapy as a salvage regimen for previously treated advanced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22220

7 January 2021

Gefitinib is more effective in never-smokers with non-small-cell lung cancer: experience among Asian patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22220

7 January 2021

Activity of gefitinib in advanced non-small-cell lung cancer with very poor performance status

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22220

7 January 2021

Evaluation of safety and efficacy of gefitinib ('iressa', zd1839) as monotherapy in a series of Chinese patients with advanced non-small-cell lung cancer: experience from a compassionate-use programme

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22220

7 January 2021

Predictors of the response to gefitinib in refractory non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22220

7 January 2021

First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer: a phase II study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22220

7 January 2021

Gefitinib as a first-line therapy of advanced or metastatic adenocarcinoma of the lung in never-smokers

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22220

7 January 2021

EGFR mutation of tumor and serum in gefitinib-treated patients with chemotherapy-naive non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22220

7 January 2021

Reporting results of cancer treatment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22220

7 January 2021

Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced nonsmall cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22220

7 January 2021

EGFR mutation conferring primary resistance to gefitinib in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22220

7 January 2021

Gefitinib as first-line, compassionate use therapy in patients with advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22220

7 January 2021

Single-agent gefitinib in patients with untreated advanced non-small-cell lung cancer and poor performance status: a Minnie Pearl Cancer Research Network Phase II Trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22220

7 January 2021

American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22220

7 January 2021

Survival of stage IIIB/IV non-small cell lung cancer patients who received chemotherapy but did not participate in clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22220

7 January 2021

Sex-associated differences in presentation and survival in patients with lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22220

7 January 2021

Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. The European Lung Cancer Working Party.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22220

7 January 2021

Gefitinib should be cautiously administered to poor performance status patients with non-small-cell lung cancer: results from a prospective feasibility study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22220

7 January 2021

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22220

7 January 2021

Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22220

7 January 2021

High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22220

7 January 2021

Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22220

7 January 2021

The EGFR mutation and its correlation with response of gefitinib in previously treated Chinese patients with advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22220

7 January 2021

Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22220

7 January 2021

Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in chinese patients with non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22220

7 January 2021

Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22220

7 January 2021

Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22220

7 January 2021

Identifiers

DOI

10.1002/CNCR.22220

1 reference

12 April 2018

PubMed ID

16989002

1 reference

12 April 2018